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ABSTRACT Cutaneous necrotizing eosinophilic vasculitis 
(CNEV) is a rare type of vasculitis. Eosinophilic vasculitis is 
a necrotizing vasculitis with eosinophilic vascular infiltra-
tion, in which eosinophils mediate vascular damage in the 
disease process. We present a case of an 18-year-old girl 
who developed palpable purpura and hemorrhagic bul-
lae over the lower extremities associated with itching, 7 
days after the commencement of penicillin therapy. Plasma 
cryofibrinogen was positive. Histopathology showed an in-
filtration of eosinophils within and around the vessel walls 
and a complete absence of nuclear dust and neutrophils. 
Oral prednisone at 1 mg/kg induced remission in 2 weeks; 
the prednisone dose was tapered and discontinued after 
2.5 months. There was no evidence of recurrence after 37 
months of follow-up. Our patient represents a rare case of 
drug/penicillin-induced CNEV associated with cryofibrino-
genemia, without systemic organ involvement.
KEY WORDS: cutaneous necrotizing eosinophilic vasculitis, 
drug-induced, penicillin, cryofibrinogenemia
INTRODUCTION
Eosinophilic vasculitis is a rare type of vasculitis 
in patients without marked hypereosinophilia or sys-
temic symptoms, with histological finding of small-
vessel necrotizing vasculitis (1). Eosinophilic vasculitis 
may be an idiopathic or primary process (2) that over-
laps with hypereosinophilic syndrome (HES), without 
specific immunoserological findings (1), or secondary 
to connective tissue diseases (CTD) (3), parasitic in-
fections, or eosinophilic granulomatosis with polyan-
giitis (EGPA) (4). 
We present a rare case of drug-induced cutaneous 
necrotizing eosinophilic vasculitis (CNEV), an unusual 
form of drug eruption triggered by penicillin, associ-
ated with cryofibrinogenemia, without systemic or-
gan involvement.
CASE REPORT
An 18-year-old girl had been treated with intra-
muscular penicillin because of tonsillopharyngitis 
and fever. Purpuric lesions appeared on her legs on 
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the 7th day of penicillin treatment. Large, tense hem-
orrhagic bullae developed within a few days. The pa-
tient reported moderate itching during the develop-
ment of new lesions. There was no fever, joint pain, or 
headache. There was no nausea, vomiting, hematuria, 
or urinary symptoms. The patient had no history of al-
lergic diseases such as asthma or allergic rhinitis. 
Physical examination showed disseminated pal-
pable purpura and hemorrhagic bullae, 5 to 20 mm in 
diameter, over the legs (Figure 1). Some lesions were 
arranged in a linear pattern (Koebner’s phenom-
enon) (Figure 2). The lower extremities were slightly 
edematous. 
Erythrocyte sedimentation rate and C-reactive 
protein were 26 mm/h and 22 mg/L (normal <5 
mg/L), respectively. Complete blood count with dif-
ferential was normal, except eosinophilia of 12.7% 
(absolute eosinophil count 952/mm3). Plasma cryofi-
brinogen was positive (++). Serum routine biochem-
istry was normal. Blood coagulation tests, C3, C4, im-
munoglobulin levels (IgG, IgA, IgM), cryoglobulins, 
antinuclear antibodies, anti-neutrophil cytoplasmic 
antibodies, and anti-streptolysin-O were normal or 
negative. Serology tests for hepatitis B, C and Ep-
stein-Barr virus were negative. Serum protein electro-
phoresis was normal, and there was no evidence of 
monoclonal gammopathy. Chest X-ray examination 
and abdominal ultrasonography were normal. The 




Skin lesions Peripheral 
eosinophilia
Immunology Other abnormalities Treatment 




1.4×109/L normal gingivitis prednisone, 
hydroxyurea




3.6×109/L IgE 218 μg/L hepatic vein occlusion, 
gingivitis
prednisone




6.2×109/L IgE 59.280 μg/L transient 






Launay, 2000 (6) 81/F purpura with 
necrotic lesions





27/F palpable purpura, 
urticarial plaques,  
angioedema
14.4×109/L ANA 1:320 no prednisone, 
betamethasone with 
suplatast tosilate
Tsunemi, 2005 (8) 53/F annular urticarial 
plaques




53/M papules, nodules, 
and ulcers






plaques and  papules
normal normal chronic periaortitis methylprednisolone,
colchicine




3.4×109/L IgE 658.3 IU/mL no prednisone,
glycyrrhizin
Sugiyama, 2013 80/F multiple purpuric 
patches




55/F erythemas 781/μL normal Budd-Chiari syndrome balloon angioplasty 
and warfarin 
for hepatic 
veins,  systemic 
corticosteroid
Riyaz, 2016 (12) 45/F multiple, discrete, 
and confluent 
purpuric papules and 
plaques, angioedema
normal normal no prednisone
Table 1. Reported cases of primary recurrent cutaneous necrotizing eosinophilic vasculitis
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The histological finding (purpuric lesion on the 
right lower leg) showed an infiltration of eosinophils 
within and around the walls of arterioles and venules 
in the dermal superficial vascular plexus (Figure 3), 
and a complete absence of neutrophils and nuclear 
dust. Fibrin deposits in the vessel walls, luminal oc-
clusions of the vessels (Figure 4), and extravasation of 
red blood cells were also present. Direct immunofluo-
rescence was negative.
The patient was initially treated with oral predni-
sone at 1 mg/kg/day with gradual dose tapering over 
2.5 months. After 9 weeks, the lesions cleared com-
pletely with residual hyperpigmentation and scar-
ring; cryofibrinogen was negative. The patient has 
not experienced any recurrence after 37 months of 
follow-up. Penicillin avoidance was recommended.
DISCUSSION
Eosinophilic vasculitis, an idiopathic disease com-
monly known as recurrent CNEV, is a rare entity first 
described in 1994. Recurrent CNEV is clinically char-
acterized by recurrent, multiple, pruritic skin lesions 
with a chronic/relapsing course and by the absence 
of any features of systemic disease or specific immu-
noserological findings. To the best of our knowledge, 
only 12 patients with RCNEV have been described in 
the literature (Table 1) (2,5-12). Patients with recur-
rent CNEV usually have peripheral blood eosinophil-
ia, but the eosinophil count does not always parallel 
the severity of the disease and some patients expe-
rience cutaneous eruption without peripheral blood 
eosinophilia. Systemic corticosteroids were effective 
in all cases; however, recurrences were common after 
treatment cessation (2,5).
HES encompasses a wide range of clinical mani-
festations sharing 3 features: 1) peripheral eosino-
philia >1500/mm3 on at least 2 occasions; 2) evidence 
of organ involvement; 3) absence of other causes of 
eosinophilia (parasite infection/infestation, atopic 
and/or allergic diseases, adverse drug reaction, hy-
poadrenalism, neoplasms, collagen-vascular disease) 
(13). However, eosinophilic vasculitis in HES is rare: 
only 8 cases have been reported so far (14). EGPA usu-
ally presents in three phases: the prodromal phase 
characterized by asthma with or without allergic rhi-
nitis; the eosinophilic phase characterized by blood 
and tissue eosinophilia; and the vasculitic phase. Eo-
sinophilic vasculitis has rarely been described in cuta-
neous vasculitic lesions of EGPA (4). Since our patient 
had mild eosinophilia and there was no evidence of 
visceral involvement, she did not fulfill the criteria for 
either HES or EGPA.
Eosinophilic vasculitis is very rarely associated 
with CTDs. This group of patients usually presents 
with pruritic, erythematous, or purpuric papules with 
peripheral blood eosinophilia and hypocomplement-
emia, and, generally, responds to corticosteroids (3). 
Our patient fulfilled no criteria for CTDs.
Based on histology, vasculitis can be classified ac-
cording to the size of vessels affected and the domi-
nant cells mediating the inflammation (neutrophilic, 
granulomatous, lymphocytic, or eosinophilic) (15). 
Histologically, eosinophilic vasculitis is a term for 
necrotizing vasculitis with eosinophilic vascular infil-
tration without leukocytoclasia (5). Eosinophilic leu-
kocytoclastic vasculitis presents with palpable pur-
pura, indistinguishable from classic leukocytoclastic 
vasculitis (LCV). It can be caused by infections, drugs, 
or other triggers, similar to classic LCV. In eosinophilic 
LCV, histopathologically, predominant eosinophils 
are found together with neutrophils, lymphocytes, 
extravasated erythrocytes, nuclear dust, fibrin in and 
around vessel walls, as well as collagen degeneration 
(16). In our case, necrotizing vasculitis of dermal small 
vessels with prominent infiltration of eosinophils 
without neutrophils and leukocytoclasia strongly 
supported the diagnosis of CNEV. Clinically, eosino-
philic vasculitis is usually accompanied by more or 
Figure 2.  Koebner’s phenomenon.
Figure 1. Palpable purpura and hemorrhagic bullae on 
both lower extremities (with marked skin discoloration 
caused by eosin).
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less severe itch, while “classical” LCV is usually not 
pruritic (2,5). 
Drug-induced LCV can also feature prominent 
blood eosinophilia and a high degree of tissue eosin-
ophilia (17). In the classical drug-induced LCV limited 
to the skin, just the discontinuation of causative drug, 
bed rest, and topical corticosteroid therapy may be 
sufficient. Only severe cases may necessitate systemic 
corticosteroid therapy (18). On the other hand, sys-
temic corticosteroids should be the first-line therapy 
in eosinophilic vasculitis for at least two reasons: a) 
to reduce blood and tissue eosinophilia, preventing 
eosinophil-mediated tissue damage; b) to prevent a 
potentially life-threatening prothrombotic state (19).
Cryofibrinogenemia may be essential or second-
ary to underlying disorders (malignancies, drugs, 
infection, vasculitis, CTDs, or associated with cryo-
globulinemia) (20). In eosinophilic vasculitis, micro-
thrombi are possibly induced by high levels of major 
basic protein released by numerous eosinophils. Ma-
jor basic protein has direct toxic effects on microvas-
cular endothelial cells, exposing collagen and thus 
causing clot formation (21). We did not detect cryofi-
brinogen deposition on serial sections of the biopsy 
performed on an early lesion, but we cannot exclude 
the possibility of later deposition of cryofibrinogen in 
previously damaged blood vessels subsequently pro-
ducing more severe necrosis resulting in blister for-
mation. It has been shown that cryofibrinogenemia 
may severely complicate (infection, sepsis) the course 
of underlying disease (20). Unfortunately, in many 
centers, cryofibrinogen is not always sought for.
CONCLUSION
CNEV is a rare or underreported disease, while 
penicillin- or other drug-induced CNEV has never 
been reported before. Furthermore, the association 
of cryofibrinogenemia and CNEV has not been re-
ported so far. New cases should be investigated to 
elucidate all the pathogenic processes active in this 
peculiar disease. 
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Figure 3. Histopathological findings: infiltration of eosino-
phils and a few lymphocytes and histiocytes around and 
within the vessel walls, luminal occlusions of the vessels 
(hematoxylin and eosin, ×200).
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